ライフサイエンスコーパス: ALCAM

1 ALCAM [activated leukocyte cell adhesion molecule (BEN/S

2 ALCAM expression on PB and SF monocytes/macrophages is e

3 ALCAM knockdown by an ALCAM-specific siRNA significantly

4 ALCAM null mutant axons were specifically compromised in

5 ALCAM shedding, defined as detection of the intracellula

6 ALCAM significantly enhanced tube formation of endotheli

7 ALCAM supports the development of hematopoietic cells as

8 ALCAM was expressed in the SC during RGC axon targeting

9 ALCAM was expressed on monocyte-lineage cells in situ in

10 ALCAM(-/-) mice displayed an altered blood vascular netw

11 st it affected the molecular weights of HB-2/ALCAM and SR-BI/CLA-1.

12 Both RT-PCR and Western blotting for HB-2/ALCAM were negative in human fetal hepatocytes while Gp9

13 tent with patterns of expression of miR-214, ALCAM, and miR-148b in human melanoma specimens.

14 This study identifies CD166/ALCAM (ALCAM) as a close structural and functional homolog of R

15 Although ALCAM expression on tumor cells has been linked to tumor

16 ALCAM knockdown by an ALCAM-specific siRNA significantly increased cell growth

17 croRNA-192 or -215 and ALCAM knockdown by an ALCAM-specific siRNA significantly increased the migrati

18 ALCAM-negative cell line, consistent with an ALCAM-L1 heterophilic molecular interaction.

19 ested in different binding assays to analyze ALCAM-CD6 interactions in more detail.

20 d is mediated in part by ICAM-1, VCAM-1, and ALCAM.

21 Upregulation of miR-214 and ALCAM and the loss of TFAP2 expression have been implica

22 Here, we link miR-214 and ALCAM as well as identify a core role for miR-214 in org

23 ection of mimics of microRNA-192 or -215 and ALCAM knockdown by an ALCAM-specific siRNA significantly

24 m of ALCAM that may have ALCAM-dependent and ALCAM-independent functions, providing further insights

25 rfering RNA show a 35% reduction in DTH, and ALCAM(-/-) RAGE(-/-) double-knockout mice show a 27% red

26 ion of the cell adhesion molecules ITGA5 and ALCAM.

27 enchymal cells are mesodermal in origin, and ALCAM(+) submesothelial cells may be a precursor for HSC

28 Mesothelial cells expressed podoplanin and ALCAM.

29 hway involving miR-214, miR-148b, TFAP2, and ALCAM that is critical for establishing distant metastas

30 Using anti-ALCAM antibodies, submesothelial and mesothelial cells w

31 SPDEF, FOXA1, XBP1, CYB5, TFF3, NAT1, APOD, ALCAM and AR (P<0.001).

32 , as well as novel deregulated genes such as ALCAM that is prognostically relevant in MM and may iden

33 crophage colony-stimulating factor augmented ALCAM expression on PB monocytes.

34 Because ALCAM has been suggested to interact with the IgSF adhes

35 Here we show that an antibody against BEN/ALCAM/SC1/DM-GRASP/MuSC selectively labels mouse SACMNs

36 al evidence of a dynamic association between ALCAM and the actin cytoskeleton, no detailed informatio

37 sALCAM demonstrated an ability to bind ALCAM and partially inhibited ALCAM-ALCAM homophilic int

38 asensitive detection of the cancer biomarker ALCAM in serum.

39 Both ALCAM and sALCAM are expressed in a variety of cultured

40 prometastatic functions directly promoted by ALCAM.

41 nflammatory cytokine bridging RAGE and CD166/ALCAM downstream effector mechanisms, both being compens

42 Blocking CD166/ALCAM expression using small interfering RNA completely

43 This study identifies CD166/ALCAM (ALCAM) as a close structural and functional homol

44 egulation of RAGE in animals devoid of CD166/ALCAM, and vice versa.

45 and it shows that binding of S100B to CD166/ALCAM induces dose- and time-dependent expression of mem

46 ing cells through its interaction with CD166/ALCAM (activated leukocyte cell adhesion molecule), and

47 and RAGE(-/-) animals pretreated with CD166/ALCAM small interfering RNA by 50% and 40%, respectively

48 CD6-ALCAM interactions mediate immune cell adhesion and are

49 Presently, the details of CD6-ALCAM interactions and of signaling through CD6 are unkn

50 e two cell surface proteins suggest that CD6-ALCAM interactions play an important role in mediating t

51 The CD6-ALCAM (activated leukocyte cell adhesion molecule) inter

52 receptor binding domain which block the CD6-ALCAM interaction.

53 Longitudinal analysis of circulating ALCAM in tumor-bearing mice revealed that shedding of tu

54 These studies have enabled us to classify ALCAM residues according to their importance for binding

55 Consistently, ALCAM(-/-) mice, but not WT mice treated with RAGE small

56 In this study, ALCAM-deficient (ALCAM(-/-)) mice were used to evaluate the role of ALCAM

57 that shedding of tumor, but not host-derived ALCAM is elevated during growth of the cancer.

58 cancer metastasis, and neuronal development, ALCAM undergoes both homotypic interactions with other A

59 Four genes (DNAH8, ALCAM, RARS, and GBF1) also demonstrated an increase in

60 ificantly reduced for patients with elevated ALCAM shedding (P = 0.01; HR, 3.0), suggesting that ALCA

61 vial fluid (SF) macrophages, and we examined ALCAM expression in situ in RA synovium by immunofluores

62 lial-like yolk sac cells that do not express ALCAM, indicating that sALCAM has an independent effect

63 reveals a novel role of stromally expressed ALCAM in supporting tumor growth and metastatic spread.

64 sociated retinal cells and an L1-expressing, ALCAM-negative cell line, consistent with an ALCAM-L1 he

65 d with retinol, suggesting the potential for ALCAM(+) cells to differentiate to HSCs.

66 Furthermore, ALCAM expression was increased in cocaine-treated mice w

67 novel soluble isoform of ALCAM that may have ALCAM-dependent and ALCAM-independent functions, providi

68 t the amino-terminal Ig-like domain of human ALCAM specifically binds to the third membrane-proximal

69 A series of truncated human ALCAM and CD6 immunoglobulin fusion proteins were produc

70 Experiments in ALCAM(-/-) animals displayed an only slight reduction of

71 tasis to the lungs was profoundly reduced in ALCAM(-/-) mice.

72 across species, and nonconserved residues in ALCAM and its murine homolog map to the beta-sheet face

73 The CD6 binding site in ALCAM is conserved across species, and nonconserved resi

74 creased permeability of CNS blood vessels in ALCAM KO animals.

75 for several cell surface proteins, including ALCAM/CD166, the Ephrin type A receptor, EGFR and the pr

76 Furthermore, in vitro culture-induced ALCAM expression on PB monocytes and CD14+ RA SF cells w

77 bility to bind ALCAM and partially inhibited ALCAM-ALCAM homophilic interactions.

78 Conversely, retention of intact ALCAM was associated with improved survival, thereby con

79 extracellular binding site of the CD6 ligand ALCAM, which is required for CD6 stimulation.

80 this platform, the cancer prognostic marker ALCAM could be detected in serum with a detection limit

81 on cell migration in addition to modulating ALCAM function.

82 activated leukocyte cell adhesion molecule (ALCAM) and C-reactive protein (CRP) (p < 0.05), and IQR

83 activated leukocyte cell adhesion molecule (ALCAM) and platelet-derived growth factor receptor alpha

84 activated leukocyte cell adhesion molecule (ALCAM) expression at the posttranscriptional level.

85 activated leukocyte cell adhesion molecule (ALCAM) has been implicated in leukocyte transmigration a

86 activated leukocyte cell adhesion molecule (ALCAM) inhibited transmigration (P </= 0.007), and CCL21

87 Activated leukocyte cell adhesion molecule (ALCAM) is a cell adhesion molecule found on blood-brain

88 Activated leukocyte cell adhesion molecule (ALCAM) is a type I transmembrane protein member of the i

89 Activated leukocyte cell adhesion molecule (ALCAM) is expressed at the surface of epithelial ovarian

90 Activated leukocyte cell adhesion molecule (ALCAM) is expressed on various cell types, including leu

91 activated leukocyte cell adhesion molecule (ALCAM) is prognostic for outcome in patients with colore

92 activated leukocyte cell adhesion molecule (ALCAM) mediates adhesion of thymocytes to thymic epithel

93 Activated leukocyte cell adhesion molecule (ALCAM) mediates cell aggregation, which is required for

94 Activated leukocyte cell adhesion molecule (ALCAM) was recently identified as a ligand for CD6, a si

95 activated leukocyte cell adhesion molecule (ALCAM), a CD6 ligand belonging to the immunoglobulin sup

96 activated leukocyte cell adhesion molecule (ALCAM), a member of the Ig superfamily, has been detecte

97 activated leukocyte cell adhesion molecule (ALCAM), a model cancer biomarker, in undiluted serum wit

98 activated leukocyte cell adhesion molecule (ALCAM), is actively shed from metastatic prostate cancer

99 -activated leukocyte cell adhesion molecule (ALCAM/CD166).

100 activated leukocyte cell adhesion molecule [ALCAM]) is a marker of colorectal cancer (CRC) stem cell

101 crophages showed that the adhesion molecules ALCAM, ICAM4, and Syndecan-2, as well as macrophage adhe

102 usion proteins containing single or multiple ALCAM or CD6 domains, we were able to determine that the

103 A total of ten new ALCAM mutants were prepared, and three additional residu

104 The absence of ALCAM expression in cells forming the stromal tumor micr

105 d in active EAE was linked to the absence of ALCAM on BBB-ECs.

106 n and metastatic spread, the contribution of ALCAM expressed in cells forming the tumor stroma to can

107 r the first time the in vivo contribution of ALCAM to angiogenesis and reveals a novel role of stroma

108 the single amino-terminal Ig-like domain of ALCAM and lacks a transmembrane domain.

109 sALCAM completely abolished these effects of ALCAM.

110 ) pathways resulted in induced expression of ALCAM.

111 es mapped to the predicted A'GFCC'C" face of ALCAM's N-terminal domain.

112 oint to a biologically important function of ALCAM in maintaining BBB integrity.

113 The reduced growth of ALCAM knockdown cells corresponded to an increase in apo

114 f RGC axons from the temporal retina half of ALCAM null mice to abnormally lateral sites in the contr

115 ings implicate cocaine-mediated induction of ALCAM as a mediator of increased monocyte adhesion/trans

116 Cocaine-mediated induction of ALCAM in human brain microvascular endothelial cells thr

117 Here, we isolated a novel soluble isoform of ALCAM (sALCAM) that is produced via alternative splicing

118 data characterize a novel soluble isoform of ALCAM that may have ALCAM-dependent and ALCAM-independen

119 Gene-specific knockdown of ALCAM in bone-metastatic PC3 cells greatly diminished bo

120 In addition, expression levels of ALCAM were significantly lower in GC than in NS.

121 ly is this posttranslational modification of ALCAM a marker of prostate cancer progression, the molec

122 Targeted mutagenesis of ALCAM reveals that residues which constitute the CD6 bin

123 The extracellular region of ALCAM includes five Ig-like domains, and its N-terminal

124 olled by TFAP2), both negative regulators of ALCAM.

125 -/-)) mice were used to evaluate the role of ALCAM in lung tumor growth and metastasis.

126 d controls, suggesting the important role of ALCAM in promoting leukocyte infiltration across the BBB

127 M, lending additional support to the role of ALCAM.

128 We now show that upregulation of ALCAM in the brain endothelium seen in HIV(+)/cocaine dr

129 This study clarifies the prognostic value of ALCAM by visualizing ectodomain shedding using a dual st

130 Previous reports on the prognostic value of ALCAM expression in CRC have been contradictory and inco

131 ive correlation between miR-214 and ITGA5 or ALCAM along with an inverse correlation of miR-214 and m

132 be overridden by overexpression of ITGA5 or ALCAM in the same tumor cells.

133 compare the contribution of these and other ALCAM residues to the CD6-ligand interaction.

134 rgoes both homotypic interactions with other ALCAM molecules and heterotypic interactions with the su

135 resent in rheumatoid synovium could regulate ALCAM cell surface expression on peripheral blood (PB) m

136 Silencing ALCAM in miR-214-overexpressing melanoma cells reduced c

137 Previously, six ALCAM residues were identified by alanine scanning mutag

138 In this study, ALCAM-deficient (ALCAM(-/-)) mice were used to evaluate

139 As a substrate, ALCAM-Fc protein promoted L1-dependent attachment of acu

140 f the interaction between the amino-terminal ALCAM domains and the membrane-proximal CD6 SRCR domain

141 vitro, and molecular analysis confirmed that ALCAM is associated with tight junction molecule assembl

142 h improved survival, thereby confirming that ALCAM shedding is associated with poor patient outcome.

143 In the present study, we found that ALCAM knockout (KO) mice developed a more severe myelin

144 tinocollicular mapping, we hypothesized that ALCAM might direct topographic targeting to the superior

145 s of prostate cancer cell lines reveals that ALCAM expression and shedding is elevated in response to

146 hedding (P = 0.01; HR, 3.0), suggesting that ALCAM shedding can identify patients with early-stage di

147 The ALCAM(+) cells expressed hepatocyte growth factor and pl

148 The ALCAM(+) cells formed intracellular lipid droplets when

149 In culture, the ALCAM(+) cells rapidly acquired myofibroblastic morpholo

150 rk to understand the stabilizing role of the ALCAM supramolecular complex engaged to CD6 during dendr

151 Together, these data demonstrate that the ALCAM is both a functional regulator as well as marker o

152 Neutralizing antibody to ALCAM ameliorated this effect.

153 retreating with the neutralizing antibody to ALCAM, lending additional support to the role of ALCAM.

154 , phenotypic characterization of unimmunized ALCAM KO mice revealed a reduced expression of BBB junct

155 miR-214 upregulated ALCAM, acting transcriptionally through TFAP2 and also p

156 Functional implication of upregulated ALCAM was confirmed using cell adhesion and transmigrati

157 and-independent supramolecular complex where ALCAM stably interacts with actin by binding to syntenin

158 ther, these results suggest a model in which ALCAM in the SC interacts with L1 on RGC axons to promot